Vitaly Margulis, M.D.

Upon completion of a B.S. degree in biology and biochemistry with highest honors at the University of Texas, and honors medical degree at The University of Texas Southwestern Medical School, I was accepted into a highly competitive urology residency at the University of Texas Southwestern Medical Center in Dallas. During residency training, additional research time was focused on minimally invasive techniques to manage small renal masses, evaluation of a novel approach to perform nephron sparing surgery utilizing radiofrequency ablation, and utilization of tissue micro-array technology to evaluate biomarkers as predictors of bladder cancer outcome. Upon completion of rigorous clinical training in urology, I have entered and completed urologic oncology fellowship at the MD Anderson Cancer Center, where my research focus was on understanding the molecular biology of renal cell carcinogenesis and progression as a model for developing novel diagnostic and therapeutic strategies for this disease. Specifically, our group investigated the role of TGF-beta signal transduction in human renal cell carcinoma with goals of developing targeted therapies. Current scientific endeavors include identification of novel biomarkers in renal cell carcinoma, which could potentially allow for timely diagnosis, staging, prognostication and identification of candidates for adjuvant systemic therapies.

Medical School	UT Southwestern Medical Center (2001)
Internship	UT Southwestern Medical Center at Dallas (2002)
Residency	UT Southwestern Medical Center at Dallas (2006)
Fellowship	MD Anderson Cancer Center (2009)

• Male Urology
• Urology

• Primary Interests
• Bladder Cancer, Masses & Tumors
• Elevated PSA
• Hematuria
• Kidney Cancer, Masses & Tumors
• Penile Cancer
• Prostate Cancer
• Retroperitoneal Fibrosis
• Testes Mass
• Testicular Cancer
• Ureteral Cancer, Masses & Tumors

• Metastatic progression and resistance to targeted therapies
• Molecular biology involved in renal cell cancer tumorigenesis

Featured Publications

Predictors of oncologic outcome after resection of locally recurrent renal cell carcinoma

Margulis V, McDonald M, Matin SF, et al The Journal of Urology April 2009 Issue 4, Volume 181 496

Type III TGF-β Receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-β signaling pathway

Vitaly Margulis, Tapati Maity, Xiu-Ying Zhang, et. al Clinical Cancer Research September 2008 14 5722-5730

Genetic Susceptibility to Renal Cell Carcinoma: The Role of DNA Double Strand Break Repair Pathway

Margulis V, Lin J, Hushan Y, et al Cancer Epidemiology, Biomarkers & Prevention September 2008 17 2366

Surgical morbidity associated with administration of targeted molecular therapy prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

Margulis V, Matin SF, Tannir N, et al The Journal of Urology July 2008 180, 1 94-98

Multi-institutional external validation of the predictive value of Ki-67 labeling index in patients treated with radical cystectomy

Margulis V, Karakiewicz P, Fradet Y, et al Journal of the National Cancer Institute January 2009 Volume 101, Number 2 114-119

• Merit Award
  American Society of Clinical Oncology (2008)
• National Institute of Health Clinical Research Scientist LRP Award
  NIH (2007)
• American Urological Association Foundation Research Scholar Award
  AFUD/AUA (2006)
• Ruth L. Kirschstein National Research Service Award
  University of Texas MD Anderson Cancer Center (2006)
• Alpha Omega Alpha
  UT Southwestern Medical School (2001)

• American Association for Cancer Research
• American Society of Clinical Oncology
• American Urological Association
• Endourologic Society
• Society of Urologic Oncology